Boosting Brain Uptake of a Therapeutic Antibody by Reducing Its Affinity for a Transcytosis Target
- 25 May 2011
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 3 (84), 84ra44
- https://doi.org/10.1126/scitranslmed.3002230
Abstract
Monoclonal antibodies have therapeutic potential for treating diseases of the central nervous system, but their accumulation in the brain is limited by the blood-brain barrier (BBB). Here, we show that reducing the affinity of an antibody for the transferrin receptor (TfR) enhances receptor-mediated transcytosis of the anti-TfR antibody across the BBB into the mouse brain where it reaches therapeutically relevant concentrations. Anti-TfR antibodies that bind with high affinity to TfR remain associated with the BBB, whereas lower-affinity anti-TfR antibody variants are released from the BBB into the brain and show a broad distribution 24 hours after dosing. We designed a bispecific antibody that binds with low affinity to TfR and with high affinity to the enzyme β-secretase (BACE1), which processes amyloid precursor protein into amyloid-β (Aβ) peptides including those associated with Alzheimer’s disease. Compared to monospecific anti-BACE1 antibody, the bispecific antibody accumulated in the mouse brain and led to a greater reduction in brain Aβ after a single systemic dose. TfR-facilitated transcytosis of this bispecific antibody across the BBB may enhance its potency as an anti-BACE1 therapy for treating Alzheimer’s disease.Keywords
This publication has 13 references indexed in Scilit:
- A Therapeutic Antibody Targeting BACE1 Inhibits Amyloid-β Production in VivoScience Translational Medicine, 2011
- Blood–Brain Barrier Transport of Therapeutics via Receptor-MediationPharmaceutical Research, 2007
- Targeting Anti—Transferrin Receptor Antibody (OX26) and OX26-Conjugated Liposomes to Brain Capillary Endothelial Cells Using In Situ PerfusionJournal of Cerebral Blood Flow & Metabolism, 2004
- Restricted transport of anti‐transferrin receptor antibody (OX26) through the blood–brain barrier in the ratJournal of Neurochemistry, 2001
- BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeuticsHuman Molecular Genetics, 2001
- β-Secretase Cleavage of Alzheimer's Amyloid Precursor Protein by the Transmembrane Aspartic Protease BACEScience, 1999
- ‘Knobs-into-holes’ engineering of antibody CH3 domains for heavy chain heterodimerizationProtein Engineering, Design and Selection, 1996
- Anti-transferrin receptor antibody and antibody-drug conjugates cross the blood-brain barrier.Proceedings of the National Academy of Sciences of the United States of America, 1991
- Receptor‐mediated transcytosis of transferrin across the blood‐brain barrierJournal of Neuroscience Research, 1987
- Transferrin receptor on endothelium of brain capillariesNature, 1984